Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.

Experimental neurology - 1 Sept 1999

Alexi T, Hughes P E, van Roon-Mom W M, Faull R L, Williams C E, Clark R G, Gluckman P D

Abstract excerpt

Huntington's disease is an incurable genetic neurological disorder characterized by the relatively selective degeneration of the striatum. Lesioning of the striatum in rodents using the excitatory amino acid agonist, quinolinic acid (QA), effectively mimics the human neuropathology seen in Huntington's disease. Using this animal model of Huntington's disease, we investigated the ability of the insulin-like growth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calbindin 2
Share to Calbindins

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Choline O-Acetyltransferase

Share to Denervation

Share to Interneurons

Share to NADPH Dehydrogenase

Share to Parvalbumins

Share to S100 Calcium Binding Protein G

Source

Identifiers

PMID: 10486177
DOI: 10.1006/exnr.1999.7168

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.PMID 10486177Read ↗

Protective effects of neurotrophin-4/5 and transforming growth factor-alpha on striatal neuronal phenotypic degeneration after excitotoxic lesioning with quinolinic acid.Semantic proximity Read ↗

Administration of recombinant human Activin-A has powerful neurotrophic effects on select striatal phenotypes in the quinolinic acid lesion model of Huntington's disease.Semantic proximity Read ↗

Brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5 differentially regulate the phenotype and prevent degenerative changes in striatal projection neurons after excitotoxicity in vivo.Semantic proximity Read ↗

Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.Semantic proximity Read ↗

Effects of excitotoxicity in the hypothalamus in transgenic mouse models of Huntington diseaseSemantic proximity Read ↗

Adenoviral gene delivery of pigment epithelium-derived factor protects striatal neurons from quinolinic acid-induced excitotoxicity.Semantic proximity Read ↗

Synaptic Dysfunction in Huntington’s Disease: Lessons from Genetic Animal ModelsSemantic proximity Read ↗

Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation.Semantic proximity Read ↗

Quantitative analysis of the generation of different striatal neuronal subtypes in the adult brain following excitotoxic injury.Semantic proximity Read ↗

Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors.Semantic proximity Read ↗

Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity.Semantic proximity Read ↗

Effects of striatal excitotoxicity on huntingtin-like immunoreactivity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.